A retrospective analysis of the use of loteprednol etabonate ophthalmic suspension 0.5% following canaloplasty
Clinical Ophthalmology Feb 22, 2018
Khaimi MA - This retrospective study was conducted to assess the use of loteprednol etabonate (LE) suspension 0.5% in glaucoma patients undergoing canaloplasty. The researcher found that canaloplasty, with or without cataract surgery managed postoperatively with LE suspension 0.5%, was effective and safe for glaucoma subjects.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
